查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585674

生物相似藥市場：按產品、適應症、製造分類 - 2025-2030 年全球預測

Biosimilars Market by Product (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Indication (Autoimmune Diseases, Blood Disorders, Chronic Diseases), Manufacturing - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

據預測，2023年生物相似藥市場價值為407億美元，預計2024年將達到499.1億美元，複合年成長率為23.31%，到2030年將達到1764.8億美元。

生物相似藥是與已批准的參考產品高度相似的生物製藥，有潛力為昂貴的生物製藥提供具有成本效益的替代品，因此製藥業已成為生物製品的重要組成部分。對生物相似藥的需求源於醫療保健成本的上升和原始生物製藥的專利到期，以及對治療癌症、糖尿病和自體免疫疾病等慢性疾病的負擔得起的治療方法的需求。其應用涵蓋腫瘤學、免疫學和內分泌學等各個治療領域，最終用戶範圍延伸至醫院、診所和研究機構。市場成長受到慢性病盛行率上升、監管支持以及醫療保健提供者對生物相似藥的接受程度提高等因素的顯著影響。此外，新興市場和製造流程的技術進步帶來了巨大的商機。為了普及和擴大生物相似藥市場，公司應專注於與醫療保健提供者的策略聯盟和積極的行銷策略。然而，挑戰仍然存在，包括嚴格的監管要求、智慧財產權的複雜性以及需要進行大規模臨床試驗來證明與參考生技藥品的相似性。另一個限制是不願開立生物相似藥，因為與原廠生技藥品相比，人們仍然擔心其有效性和安全性。儘管有這些障礙，該領域仍有豐富的創新途徑，包括改善生物相似藥開發流程、加強藥物安全檢測系統和最佳化供應鏈效率等。公司應該投資於改善相容性生物相似藥配方的研究，這將能夠在藥房層面實現自動替代並提高市場滲透率。由於專利到期和研發投入高，生物相似藥市場的特點是競爭激烈，需要持續創新和適應性行銷才能滿足全球對生物製藥。

主要市場統計
基準年[2023] 407億美元
預測年份 [2024] 499.1億美元
預測年份 [2030] 1764.8億美元
複合年成長率（%） 23.31%

市場動態：揭示快速發展的生物相似藥市場的關鍵市場洞察

供需的動態相互作用正在改變生物相似藥市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 製藥業醫療保健支出增加
    • 對成本低於原廠生技藥品的生物相似藥的需求不斷增加
  • 市場限制因素
    • 醫生不願意開立生物相似藥
  • 市場機會
    • 改進生物相似藥製造程序
    • 政府對生物相似藥開發的支持措施
  • 市場挑戰
    • 嚴格的監管要求和法律

波特五力：駕馭生物相似藥市場的策略工具

波特的五力架構是了解生物相似藥市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解生物相似藥市場的外部影響

外部宏觀環境因素在塑造生物相似藥市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解生物相似藥市場的競爭狀況

對生物相似藥市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣生物相似藥市場供應商績效評估

FPNV定位矩陣是評估生物相似藥市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了生物相似藥市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，生物相似藥市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 製藥業醫療保健支出增加
      • 對成本低於原始生物製藥的生物相似藥的需求增加
    • 抑制因素
      • 醫生不願意開立生物相似藥
    • 機會
      • 改進生物相似藥製造程序
      • 政府支持生物相似藥開發的舉措
    • 任務
      • 嚴格的監管要求和法律
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章生物相似藥市場：依產品

  • 重組糖化蛋白
    • 促紅血球生成素
    • 促濾泡素
    • 單株抗體
      • Adalimumab
      • Infliximab
      • Rituximab
  • 重組非糖基化蛋白
    • 顆粒細胞增生因子
    • 胰島素
    • 干擾素
      • α干擾素
      • BETA型干擾素
    • 重組人體生長荷爾蒙
  • 重組勝胜肽
    • 抑鈣素
    • 升糖素

第7章依適應症分類的生物相似藥市場

  • 自體免疫疾病
  • 血液疾病
  • 慢性疾病
  • 生長激素缺乏症
  • 感染疾病
  • 腫瘤學

第8章 生物相似藥市場製造業

  • 契約製造
  • 內部製造

第9章美洲生物相似藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太生物相似藥市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的生物相似藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Alvotech
  • Amgen Inc.
  • Apotex Inc.
  • Biocon Limited
  • BioFactura, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH.
  • Catalent, Inc
  • Celltrion Healthcare Co.,Ltd.
  • Coherus BioSciences
  • Dr. Reddy's Laboratories Limited
  • Eden Biologics, Inc.
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi
  • Innovent Biologics, Inc.
  • Intas Pharmaceuticals Ltd.
  • Kashiv BioSciences, LLC.
  • Merck & Co., Inc.
  • NeuClone
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Shanghai Henlius Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-4358917D6590

The Biosimilars Market was valued at USD 40.70 billion in 2023, expected to reach USD 49.91 billion in 2024, and is projected to grow at a CAGR of 23.31%, to USD 176.48 billion by 2030.

Biosimilars, biologic medical products highly similar to already authorized reference products, represent a key segment within the pharmaceutical industry due to their potential to offer cost-effective alternatives to expensive biologics. The necessity for biosimilars arises from increasing healthcare costs and patent expirations of original biologics, driving demand for affordable therapies in treating chronic diseases like cancer, diabetes, and autoimmune disorders. Their applications span across various therapeutic areas, including oncology, immunology, and endocrinology, with end-user scope extending to hospitals, clinics, and research institutes. Market growth is heavily influenced by factors such as rising incidences of chronic diseases, regulatory support, and healthcare providers' growing acceptance of biosimilars. Moreover, emerging markets and technological advancements in manufacturing processes present substantial opportunities. Businesses should focus on strategic collaborations with healthcare providers and aggressive marketing strategies to enhance biosimilar adoption and expand market reach. However, challenges persist, including stringent regulatory requirements, intellectual property complexities, and the need for extensive clinical trials to establish similarity to reference biologics. Another limitation is the hesitancy in prescribing biosimilars due to lingering concerns regarding efficacy and safety compared to original biologics. Despite these hurdles, the sector holds rich avenues for innovation, particularly in improving biosimilar development processes, enhancing pharmacovigilance systems, and optimizing supply chain efficiencies. Companies should invest in research focused on improving interchangeable biosimilar formulations, which can lead to automatic substitution at the pharmacy level, thereby increasing market penetration. The biosimilars market is characterized by intense competition driven by patent expirations and high research and development investments, suggesting that staying ahead necessitates continuous innovation and adaptive marketing strategies to capitalize on burgeoning global demand for biologic treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 40.70 billion
Estimated Year [2024] USD 49.91 billion
Forecast Year [2030] USD 176.48 billion
CAGR (%) 23.31%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biosimilars Market

The Biosimilars Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure into the pharmaceutical industry
    • Increasing demand for lower cost biosimilars drugs than original biologics
  • Market Restraints
    • Reluctance of physicians to prescribe biosimilars
  • Market Opportunities
    • Improvements in biosimilar production processes
    • Supportive government initiative to develop biosimilars
  • Market Challenges
    • Stringent regulatory requirements and laws

Porter's Five Forces: A Strategic Tool for Navigating the Biosimilars Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biosimilars Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biosimilars Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biosimilars Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biosimilars Market

A detailed market share analysis in the Biosimilars Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biosimilars Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biosimilars Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biosimilars Market

A strategic analysis of the Biosimilars Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biosimilars Market, highlighting leading vendors and their innovative profiles. These include Alvotech, Amgen Inc., Apotex Inc., Biocon Limited, BioFactura, Inc., Biogen Inc., Boehringer Ingelheim International GmbH., Catalent, Inc, Celltrion Healthcare Co.,Ltd., Coherus BioSciences, Dr. Reddy's Laboratories Limited, Eden Biologics, Inc., F. Hoffmann-La Roche AG, Fresenius Kabi, Innovent Biologics, Inc., Intas Pharmaceuticals Ltd., Kashiv BioSciences, LLC., Merck & Co., Inc., NeuClone, Nippon Kayaku Co., Ltd., Novartis AG, Panacea Biotec Limited, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi S.A., Shanghai Henlius Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Biosimilars Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.
  • Based on Indication, market is studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.
  • Based on Manufacturing, market is studied across Contract Manufacturing and In-House Manufacturing.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure into the pharmaceutical industry
      • 5.1.1.2. Increasing demand for lower cost biosimilars drugs than original biologics
    • 5.1.2. Restraints
      • 5.1.2.1. Reluctance of physicians to prescribe biosimilars
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in biosimilar production processes
      • 5.1.3.2. Supportive government initiative to develop biosimilars
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and laws
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimilars Market, by Product

  • 6.1. Introduction
  • 6.2. Recombinant Glycosylated Proteins
    • 6.2.1. Erythropoietin
    • 6.2.2. Follitropin
    • 6.2.3. Monoclonal Antibodies
      • 6.2.3.1. Adalimumab
      • 6.2.3.2. Infliximab
      • 6.2.3.3. Rituximab
  • 6.3. Recombinant Non-Glycosylated Proteins
    • 6.3.1. Granulocyte Colony-Stimulating Factor
    • 6.3.2. Insulin
    • 6.3.3. Interferons
      • 6.3.3.1. Interferon-Alpha
      • 6.3.3.2. Interferon-Beta
    • 6.3.4. Recombinant Human Growth Hormone
  • 6.4. Recombinant Peptides
    • 6.4.1. Calcitonin
    • 6.4.2. Glucagon

7. Biosimilars Market, by Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Diseases
  • 7.3. Blood Disorders
  • 7.4. Chronic Diseases
  • 7.5. Growth Hormone Deficiency
  • 7.6. Infectious Diseases
  • 7.7. Oncology

8. Biosimilars Market, by Manufacturing

  • 8.1. Introduction
  • 8.2. Contract Manufacturing
  • 8.3. In-House Manufacturing

9. Americas Biosimilars Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Biosimilars Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvotech
  • 2. Amgen Inc.
  • 3. Apotex Inc.
  • 4. Biocon Limited
  • 5. BioFactura, Inc.
  • 6. Biogen Inc.
  • 7. Boehringer Ingelheim International GmbH.
  • 8. Catalent, Inc
  • 9. Celltrion Healthcare Co.,Ltd.
  • 10. Coherus BioSciences
  • 11. Dr. Reddy's Laboratories Limited
  • 12. Eden Biologics, Inc.
  • 13. F. Hoffmann-La Roche AG
  • 14. Fresenius Kabi
  • 15. Innovent Biologics, Inc.
  • 16. Intas Pharmaceuticals Ltd.
  • 17. Kashiv BioSciences, LLC.
  • 18. Merck & Co., Inc.
  • 19. NeuClone
  • 20. Nippon Kayaku Co., Ltd.
  • 21. Novartis AG
  • 22. Panacea Biotec Limited
  • 23. Pfizer Inc.
  • 24. Samsung Bioepis Co., Ltd.
  • 25. Sanofi S.A.
  • 26. Shanghai Henlius Biotech, Inc.
  • 27. Teva Pharmaceutical Industries Ltd.
  • 28. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. BIOSIMILARS MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMILARS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMILARS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMILARS MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ERYTHROPOIETIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY FOLLITROPIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-ALPHA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERON-BETA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMILARS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMILARS MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMILARS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND BIOSIMILARS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY BIOSIMILARS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY BIOSIMILARS MARKET SIZE, BY INTERFERONS, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, 2018-2030 (USD MILLION)

TABLE 354